🎉 M&A multiples are live!
Check it out!

Avalo Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Avalo Therapeutics and similar public comparables like Vivoryon Therapeutics, Benevolent AI, and Julphar.

Avalo Therapeutics Overview

About Avalo Therapeutics

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).


Founded

2011

HQ

United States of America
Employees

23

Website

avalotx.com

Financials

LTM Revenue $0.3M

LTM EBITDA n/a

EV

-$76.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Avalo Therapeutics Financials

Avalo Therapeutics has a last 12-month revenue of $0.3M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Avalo Therapeutics achieved revenue of $0.4M and an EBITDA of -$68.3M.

Avalo Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Avalo Therapeutics valuation multiples based on analyst estimates

Avalo Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.9M $0.4M XXX XXX XXX
Gross Profit $14.6M $0.6M XXX XXX XXX
Gross Margin 760% 145% XXX XXX XXX
EBITDA -$23.3M -$68.3M XXX XXX XXX
EBITDA Margin -1210% -15497% XXX XXX XXX
Net Profit -$41.7M -$31.5M XXX XXX XXX
Net Margin -2165% -7153% XXX XXX XXX
Net Debt $6.2M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Avalo Therapeutics Stock Performance

As of April 15, 2025, Avalo Therapeutics's stock price is $5.

Avalo Therapeutics has current market cap of $57.4M, and EV of -$76.6M.

See Avalo Therapeutics trading valuation data

Avalo Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$76.6M $57.4M XXX XXX XXX XXX $-16.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Avalo Therapeutics Valuation Multiples

As of April 15, 2025, Avalo Therapeutics has market cap of $57.4M and EV of -$76.6M.

Avalo Therapeutics's trades at -243.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Avalo Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Avalo Therapeutics and 10K+ public comps

Avalo Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$76.6M XXX XXX XXX
EV/Revenue -173.6x XXX XXX XXX
EV/EBITDA 1.1x XXX XXX XXX
P/E -1.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Avalo Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Avalo Therapeutics Valuation Multiples

Avalo Therapeutics's NTM/LTM revenue growth is -100%

Avalo Therapeutics's revenue per employee for the last fiscal year averaged $19K, while opex per employee averaged $3.0M for the same period.

Over next 12 months, Avalo Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Avalo Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Avalo Therapeutics and other 10K+ public comps

Avalo Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -77% XXX XXX XXX XXX
EBITDA Margin -15497% XXX XXX XXX XXX
EBITDA Growth 193% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $19K XXX XXX XXX XXX
Opex per Employee $3.0M XXX XXX XXX XXX
S&M Expenses to Revenue 179% XXX XXX XXX XXX
G&A Expenses to Revenue 3731% XXX XXX XXX XXX
R&D Expenses to Revenue 11809% XXX XXX XXX XXX
Opex to Revenue 15719% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Avalo Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Avalo Therapeutics M&A and Investment Activity

Avalo Therapeutics acquired  XXX companies to date.

Last acquisition by Avalo Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Avalo Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Avalo Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Avalo Therapeutics

When was Avalo Therapeutics founded? Avalo Therapeutics was founded in 2011.
Where is Avalo Therapeutics headquartered? Avalo Therapeutics is headquartered in United States of America.
How many employees does Avalo Therapeutics have? As of today, Avalo Therapeutics has 23 employees.
Who is the CEO of Avalo Therapeutics? Avalo Therapeutics's CEO is Dr. Garry A. Neil, M.D..
Is Avalo Therapeutics publicy listed? Yes, Avalo Therapeutics is a public company listed on NAS.
What is the stock symbol of Avalo Therapeutics? Avalo Therapeutics trades under AVTX ticker.
When did Avalo Therapeutics go public? Avalo Therapeutics went public in 2015.
Who are competitors of Avalo Therapeutics? Similar companies to Avalo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Avalo Therapeutics? Avalo Therapeutics's current market cap is $57.4M
What is the current revenue of Avalo Therapeutics? Avalo Therapeutics's last 12-month revenue is $0.3M.
What is the current EV/Revenue multiple of Avalo Therapeutics? Current revenue multiple of Avalo Therapeutics is -243.7x.
What is the current revenue growth of Avalo Therapeutics? Avalo Therapeutics revenue growth between 2023 and 2024 was -77%.
Is Avalo Therapeutics profitable? Yes, Avalo Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.